Please note, this programme name changed from Myeloproliferative Neoplasms Gene Panels (Pilot - Not Accredited) on 1st April 2022.
This scheme is designed for laboratories performing Myeloproliferative Neoplasms (MPN) testing using current diagnostic algorithms (Tefferi & Pardanani, 2014) to diagnose and subtype the disease. One sample will be issued in each round (two rounds per year) alongside clinical scenarios. Participants will be expected to test the samples according to their current testing pathways, and testing will be limited to the core pathogenic MPN variants, as per WHO/NCCN guidance: JAK2 (V617F and exon 12), CALR exon 9 and MPL exon 10 pathogenic variants. Testing of all these regions is not mandatory.
Extended next generation sequencing panel data is no longer included in this programme; such testing is now incorporated into the new Myeloid Gene Panels (Pilot – Not Accredited) programme. Click here
Pre issue testing of samples for this programme may be subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.
***New for 2024-2025***
As panel testing of JAK2, CALR and MPL becomes more prevalent in the diagnosis of myeloproliferative neoplasms, UK NEQAS LI has begun the process of merging the current JAK2 p.Val617Phe Mutation Status and MPN Diagnostic Testing Programmes to provide a more cost effective service whilst maintaining the rigour of the current programmes. It is intended that this process will be completed for the 2024-2025 registration period; further information will be provided in due course.
Tefferi, A & Pardanani, A (2014) Nat Rev Clin Oncol 11: 125–126
To register for this programme, please click here.